OP-724

DRUG2 trials

Sponsors

Kiminori Kimura, MD

Conditions

Liver CirrhosisLiver Cirrhosis, BiliaryPrimary Biliary Cholangitis (PBC)

Phase 1

Safety, Tolerability of OP-724 in Patients With Primary Biliary Cholangitis (Phase I)

CompletedNCT04047160

Kiminori Kimura, MDLiver Cirrhosis, Biliary, Primary Biliary Cholangitis (PBC)

Start: 2019-08-29End: 2022-03-31Updated: 2022-07-07

Safety and Tolerability Study of OP-724 in Liver Cirrhosis Patients by HIV/HCV with Hemophilia.

CompletedNCT04688034

Kiminori Kimura, MDLiver Cirrhosis

Start: 2021-03-15End: 2022-07-05Updated: 2024-10-21

Related Papers

Safety and tolerability of OP-724 in patients with haemophilia and liver cirrhosis due to HIV/HCV coinfection: an investigator-initiated, open-label, non-randomised, single-centre, phase I study

BMJ Open Gastroenterology2024-04-012 citations

Feasibility, safety and tolerability of the CREB-binding protein/β-catenin inhibitor OP-724 in patients with advanced primary biliary cholangitis: an investigator-initiated, open-label, non-randomised, two-centre, phase 1 study

BMJ Open Gastroenterology2022-11-0113 citations